Increased pediatric multiple sclerosis (MS) risk is linked to obesity, and obese patients did not respond well to first-line medications, reveals a new study. The findings of the study are published in the journal JAMA Neurology.
A single-center study of 453 children in Germany with multiple sclerosis (MS) investigated the association of obesity with pediatric MS risk and with the response of first-line therapy in children with MS.
Advertisement
‘Obesity is significantly associated with a raised risk of pediatric multiple sclerosis and with worse treatment response to first-line treatment. Hence, a healthy weight may possibly optimize treatment outcomes and decrease the disease burden and costs.
’
Read More..
Read More..
In this single-center study of 453 German children with a multiple sclerosis diagnosis, obesity was connected with twofold greater odds of the disease and more frequent failure of first-line therapy with interferon beta-1a or 1b and glatiramer acetate, thereby increasing the number of patients on second-line treatment.
In this study, increased pediatric MS risk appeared to be associated with obesity, and obese patients did not respond well to first-line medicines; altered pharmacokinetics appeared to be most likely factors in treatment response, implying that gaining healthy weight or adjusting the dose according to BMI could improve therapy response.
Source: Eurekalert
Source: Eurekalert
Advertisement
Advertisement
This site complies with the 
